Uploaded November 2026 | Updated November 2026, 4 hours ago
Health systems still tend to judge success through clinical events, short-term outcomes and service activity. But for many people living with a long-standing illness (just over a third of EU citizens aged over 16 in 2024), what matters most is staying independent, preserving cognitive function, managing fatigue, remaining in work and maintaining quality of life over time. Multiple sclerosis (MS) offers a particularly clear example of why short-term, clinical metrics do not tell the full story; progression is not only defined by relapse or mobility decline, but also by less visible changes in cognition, energy, daily functioning and independence that can have profound long-term consequences. If health systems want to deliver more patient-centred care, how should they measure outcomes and what should count as success?
Moderator: Elizabeth Sukkar, senior research manager, global health and sustainability, policy & insights, Economist Enterprise
Janneke van Wingerden, senior global medical director, neurology, Sanofi
Supported by Sanofi
Health systems still tend to judge success through clinical events, short-term outcomes and service activity. But for many people living with a long-standing illness (just over a third of EU citizens aged over 16 in 2024), what matters most is staying independent, preserving cognitive function, managing fatigue, remaining in work and maintaining quality of life over time. Multiple sclerosis (MS) offers a particularly clear example of why short-term, clinical metrics do not tell the full story; progression is not only defined by relapse or mobility decline, but also by less visible changes in cognition, energy, daily functioning and independence that can have profound long-term consequences. If health systems want to deliver more patient-centred care, how should they measure outcomes and what should count as success?
Moderator: Elizabeth Sukkar, senior research manager, global health and sustainability, policy & insights, Economist Enterprise
Janneke van Wingerden, senior global medical director, neurology, Sanofi
Supported by Sanofi










